

Impact of fish oils on the outcomes of a mouse model of acute *Pseudomonas aeruginosa* pulmonary infection

Emilie Caron¹, Jean-Luc Desseyn¹, Luce Sergent², Nana Bartke³, Marie-Odile Husson¹, Alain Duhamel⁴ and Frédéric Gottrand^{1*}

¹Inserm U995, Team 4, IFR 114, University Lille Nord de France, Lille 59045, France

²Copalis, Boulogne-sur-Mer 62203, France

³Nutricia Research, Uppsalaalan 12, 3584CT Utrecht, The Netherlands

⁴Unit of Biostatistics, CERIM, EA2694, UDSL, University Lille Nord de France, Lille, France

(Submitted 2 April 2014 – Final revision received 15 October 2014 – Accepted 21 October 2014)

Abstract

Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that causes pneumonia in immunocompromised humans and severe pulmonary damage in patients with cystic fibrosis. Imbalanced fatty acid incorporation in membranes, including increased arachidonic acid and decreased DHA concentrations, is known to play a critical role in chronic inflammation associated with bacterial infection. Other lipids, such as EPA and alkylglycerols, are also known to play a role in inflammation, particularly by stimulating the immune system, decreasing inflammation and inhibiting bacterial growth. In this context, the goal of the present study was to assess the effect of dietary DHA/EPA, in a 2:1 ratio, and alkylglycerols, as natural compounds extracted from oils of rays and chimeras, respectively, on the inflammatory reaction induced by *P. aeruginosa* pulmonary infection in mice. To this end, mice were fed with a control diet or isolipidic, isoenergetic diets prepared with oils enriched in DHA/EPA (2:1) or alkylglycerols for 5 weeks before the induction of acute *P. aeruginosa* lung infection by endotracheal instillation. In our model, DHA/EPA (2:1) significantly improved the survival of mice after infection, which was associated with the acceleration of bacterial clearance and the resolution of inflammation leading to the improvement of pulmonary injuries. By contrast, alkylglycerols did not affect the outcomes of *P. aeruginosa* infection. Our findings suggest that supplementation with ray oil enriched in DHA/EPA (2:1) can be considered as a preventive treatment for patients at risk for *P. aeruginosa* infection.

Key words: *Pseudomonas aeruginosa* infection: *n*-3 Long-chain PUFA: Alkylglycerols: Inflammation

Pseudomonas aeruginosa is a Gram-negative bacterium and an opportunistic pathogen that exhibits resistance to most available antibiotics⁽¹⁾. *P. aeruginosa* is involved in nosocomial infections and is the predominant pathogen in the lungs of patients with cystic fibrosis⁽²⁾. *P. aeruginosa* infection promotes an abnormal, up-regulated pro-inflammatory cytokine profile and inhibits host immune responses that contribute to its pathogenicity^(3,4). The failure to clear infection causes massive and persistent neutrophil influx, which can directly damage tissues and cause additional increases in pro-inflammatory cytokines, leading to bronchiectasis and fibrosis, followed by respiratory failure and death⁽⁵⁾. In this context, breaking the cycle of repetitive and eventually persistent infections, inflammation and influx of neutrophils is critical to treat cystic fibrosis successfully.

A growing number of studies have demonstrated an important role of specific dietary lipids in health and disease.

n-3 Long-chain (LC) PUFA and alkylglycerols are two different lipids that abundantly accumulate in the liver of certain species of marine fish, such as rays and chimeras, respectively. *n*-3 LC-PUFA mainly exhibit anti-inflammatory properties by promoting the synthesis of anti-inflammatory factors and inhibiting *n*-6 LC-PUFA-induced inflammation (for a review, see Miles & Calder⁽⁶⁾). Dietary *n*-3 LC-PUFA, mainly EPA and to a lesser extent DHA in a 2:1 ratio, play a key role in improving the outcomes of lung infections resulting from *P. aeruginosa*^(7,8). Although EPA and DHA are grouped together as the *n*-3 PUFA, there is substantial evidence suggesting that the individual fatty acids may have selective and potentially independent effects (for a review, see Anderson & Ma⁽⁹⁾). In most dietary sources of *n*-3 LC-PUFA used in previous experiments, EPA was more abundant than DHA in a 2:1 ratio, suggesting that most of the anti-inflammatory effects observed were mainly due to EPA. However, it remains

Abbreviations: BALF, bronchoalveolar lavage fluid; LC-PUFA, long-chain PUFA.

* **Corresponding author:** F. Gottrand, fax +33 320446134, email frederic.gottrand@chru-lille.fr

Table 1. Composition of the experimental diets*

Composition (g/kg diet)	AIN-93G
Maize starch	397.5
Casein	200
Dextrinised maize starch	132
Sucrose	100
Fat blend	70
Fibre	50
Mineral mix	35
Vitamin mix	10
L-Cystein	3
Choline bitartrate	2.5
Tertiary butylhydroquinone	0.014

AIN-93G, American Institute of Nutrition-93 Growth.

* Control, DHA/EPA (2:1) and alkylglycerol diets were adapted from the AIN-93G rodent diet. Each of the diets presents a similar distribution of the AIN-93G compounds except for the lipid content that was adapted in order to supply DHA/EPA in a 2:1 ratio and alkylglycerols for two of the diets without affecting the energy and lipid contents.

unclear whether DHA alone or in a DHA/EPA mixture with a 2:1 ratio is able to improve pulmonary inflammation induced by *P. aeruginosa* infection and more importantly to increase the survival rate after the infection.

Alkylglycerols are bioactive ether lipids particularly abundant in oil extracted from the liver of sharks and chimeras where they constitute up to 50% of the lipid fraction. Alkylglycerols have been shown to play a critical role in the modulation of immunity by enhancing macrophage activation and increasing plasma levels of Ig in rodents^(10–13). Besides their roles at the host level, *in vitro* studies have indicated alkylglycerols to be antimicrobial agents^(14,15).

In this context, the aim of the present study was to test the impact of (1) an *n*-3 PUFA mixture enriched in DHA/EPA with a 2:1 ratio and (2) alkylglycerols on the survival of mice subjected to an acute *P. aeruginosa* lung infection. To test this hypothesis, oils extracted from rays and chimeras, naturally enriched in DHA/EPA (2:1) and alkylglycerols, respectively, were incorporated in diets and given to mice for 5 weeks before the induction of *P. aeruginosa* infection. The impact of the diets on the survival rate was evaluated, and we particularly focused on the inflammatory status and pulmonary functions of the infected mice to assess the influence of those lipids on their immune system.

Materials and methods

Mice and diets

Male C57BL/6 mice (Janvier), aged 5 weeks old, were provided food and water *ad libitum* and housed in a light-controlled (12h light–12h dark, lights on at 07.00 hours) and temperature-controlled (20°C) environment.

The control, DHA/EPA (2:1) and alkylglycerol diets were adapted from the AIN-93G (American Institute of Nutrition-93 Growth) rodent diet (American Institute of Nutrition⁽¹⁶⁾) and presented the same content of energy, proteins, minerals, micronutrients and vitamins (Table 1). Briefly, lipids from soyabean oil were substituted with an isoenergetic amount of vegetable oil mixture for the control diet and with an

isoenergetic amount of vegetable oil mixture plus oils extracted from the liver of rays and chimeras, which naturally demonstrate a high rate of DHA/EPA in a 2:1 ratio or alkylglycerols, respectively, for the diets enriched in DHA/EPA (2:1) and alkylglycerols (Table 2). Fish oils were extracted from rays and chimeras, and provided by Copalis and used by Nutricia Research to prepare the diets. Our aim was to supply the mice in each group with the same amounts of α -linolenic acid (18:3 n -3) and linoleic acid (18:2 n -6), the precursors of *n*-3 and *n*-6 PUFA, respectively, and to substitute the lipids of the AIN-93G diet with either ray oil, naturally enriched in DHA/EPA (2:1), or chimera oil, naturally enriched in alkylglycerols (10 g/kg diet); the control diet had none of these compounds (Table 3). Mice were randomised into three groups and fed with the control diet or the isoenergetic, isolipidic diets containing DHA/EPA (2:1) or alkylglycerols for 5 weeks before the induction of *P. aeruginosa* infection and until the end of the protocols.

Acute *Pseudomonas aeruginosa* pulmonary infection and survival

The *P. aeruginosa* strain O1 (PAO1) was grown overnight (14 h) in Luria broth medium in a shaking and temperature-controlled (37°C) environment. The bacteria were then pelleted, washed twice and grown in fresh Luria broth for 3 h at 37°C. Once the exponential phase was reached, the bacteria were pelleted, washed twice and resuspended in 0.9% sterile saline buffer to obtain 1×10^9 colony-forming units/ml. Male C57BL/6 mice, aged 10 weeks old, were anaesthetised with sevoflurane inhalation (Sevorane; Abbott) and placed in dorsal recumbency for endotracheal instillation of 50 μ l of the PAO1 suspension (5×10^7 colony-forming units/mouse) using a 24 G animal feeding needle. Mice were then checked and weighed daily; survival was assessed over a period of 10 d after the onset of the infection.

Pulmonary bacterial clearance

Mice were killed at 8, 24 or 36 h after the instillation of *P. aeruginosa* for the evaluation of pulmonary bacterial load. Briefly, the lungs were excised aseptically, weighed and homogenised in 0.9% sterile saline buffer. To determine the number of *P. aeruginosa* colony-forming units, a 100 μ l aliquot of the homogenates was

Table 2. Composition of fat blends*

Fat blend (g/100 g lipids)	Control	DHA/EPA (2:1)	Alkylglycerols
Milk fat	37.5	0	18.34
Rapeseed oil	38	1.98	18.34
Trisun 80 oil	19.5	0	24.76
Maize oil	5	18.61	13.76
Linseed oil	0	4.22	2.75
Palm oil	0	0	13.76
Ray oil	0	75.2	0
Chimera oil	0	0	8.29

* Lipids (from soyabean oil) were substituted by three different isoenergetic fat blends: vegetable oil mixture for the control diet; vegetable oil mixture plus ray oil for the DHA/EPA (2:1) diet; vegetable oil mixture plus chimera oil for the alkylglycerol diet.

Table 3. Fatty acid composition of the experimental diets*

	Control	DHA/EPA (2:1)			Alkylglycerols		
		Ray oil (89.5 ml/100 g lipids)	Fat blend (24.81 g/100 g lipids)	Total (g/100 g lipids)	Chimera oil (11.86 ml/100 g lipids)	Fat blend (91.71 g/100 g lipids)	Total (g/100 g lipids)
Fatty acids (g/100 g lipids)							
Palmitic acid (16:0)	16.37	12.93	0	12.93	0.94	14.97	15.91
Stearic acid (18:0)	5.23	1.43	0	1.43	0.36	4.77	5.13
Total SFA	31.49	20.23	0	20.23	1.57	28.73	30.30
Total MUFA	50.48	29.47	9.59	39.06	5.77	45.4	51.17
Linoleic acid (18:2n-6)	13.96	1.43	12.51	13.94	0.08	13.86	13.94
α-Linolenic acid (18:3n-3)	3.75	0.97	2.71	3.68	0	3.68	3.68
Stearidonic acid (18:4n-3)	0	2.03	0	2.03	<0.1	0	<0.1
Arachidonic acid (20:4n-6)	0	0.44	0	0.44	<0.1	0	<0.1
EPA (20:5n-3)	0	5.11	0	5.11	0.10	0	0.1
DHA (22:6n-3)	0	10.60	0	10.60	0.16	0	0.16
Total PUFA	18.03	25.48	15.23	40.71	0.94	17.59	18.53
Total fatty acids	100	75.18	24.82	100	8.28	91.72	100
Ether lipids							
Alkylglycerols	0	0	0	0	14.28	0	14.28

* The lipid mixtures obtained from vegetable oils or vegetable oils plus ray or chimera oils were isolipidic and isoenergetic. Our aim was to supply the mice in each group with the same amounts of α-linolenic acid (18:3n-3) and linoleic acid (18:2n-6), the precursors of n-3 and n-6 PUFA, respectively.

inoculated quantitatively by 10-fold serial dilutions on bromocresol purple agar plates (Biomérieux Laboratories) and incubated for 24 h at 37°C.

Bronchoalveolar lavage

Bronchoalveolar lavages were performed by inserting a blunt 20 G needle in the trachea and injecting/reaspirating 0.5 ml followed by 1 ml of 0.9% sterile saline in the lungs. Samples (1.2–1.5 ml) of the bronchoalveolar lavage fluid (BALF) were collected from the infected lungs and centrifuged for 10 min at 1000 g. The supernatant or BALF was processed for cytokine assays while the pellet was resuspended in 1 ml of 0.9% sterile saline to determine the proportion of neutrophils and macrophages. Briefly, the cells collected from the lungs of the infected mice were counted and organised in monolayers with a cyto-centrifuge (Thermo Electron). The cells were stained with Wright–Giemsa solutions (CML) for the determination of different morphotypes. Proportions of neutrophils and macrophages were obtained from the samples of 200 cells per mouse.

Cytokine assays

Lung homogenates and the BALF were used to quantify the concentrations of IL-10 and TNF-α, respectively, in mice infected with *P. aeruginosa* using ELISA kits (BD System). Absorbance at 450 nm was determined using a microplate reader, which was used to quantify the concentrations of IL-10 and TNF-α in the lungs homogenised in 0.9% sterile saline or the BALF collected from mice in each group.

Alveolar–capillary barrier permeability

Mice from the control, DHA/EPA (2:1) and alkylglycerol groups were injected intraperitoneally with 0.2 mg fluorescein isothiocyanate (FITC)-albumin diluted in 0.9% sterile saline at

6, 14 and 34 h after the onset of the infection. At 2 h later, mice were killed, blood was collected by cardiac puncture and bronchoalveolar lavages were performed as described above. Alveolar–capillary barrier permeability was determined by calculating the ratio between the fluorescence measured in the BALF and in the serum.

Time points of the study

Based on previous experiments⁽⁸⁾ and the survival rate of mice in the present study, bacterial load and expression of the anti-inflammatory molecule IL-10 were assessed in the lungs of mice at 8, 24 and 36 h after the onset of the infection. We evaluated the expression of the pro-inflammatory molecule TNF-α, the recruitment of neutrophils and macrophages, and pulmonary injuries in the BALF of mice at 8, 16 and 36 h after the onset of the infection.

Statistical analysis

Results are presented as means with their standard errors. Multiple comparisons were analysed using a two-way ANOVA with two independent factors (diet and time of infection). Multiple comparisons between the treatment groups and the control group were corrected with Dunnett's test. Multiple comparisons within groups between the different time points of infection were corrected using Tukey's test. Cumulative survival rates were compared using the log-rank statistical analysis. The threshold for significance was set at $P < 0.05$.

Ethics statement

The protocols used herein were approved by the INSERM guidelines for the care and use of laboratory animals and by the Animal Care Ethics Committee of the region Nord-Pas-de-Calais (protocol CEEA 142011). The animals and




Fig. 1. Impact of diets enriched in DHA/EPA (2:1) and alkylglycerols on survival to *Pseudomonas aeruginosa* pulmonary infection. (a) Data represent the percentage of the survival of mice in each group. *P. aeruginosa* infection was instilled at day 0 (5×10^7 colony-forming units/mouse). *Survival was significantly increased in mice fed with the DHA/EPA (2:1) diet compared with the control diet ($P < 0.05$). (b) Body mass (BM) after the onset of *P. aeruginosa* lung infection in mice fed the control, DHA/EPA or alkylglycerol diet for 5 weeks. Data represent the percentage of initial BM. Control group, n 31 (—●—); alkylglycerol group, n 26 (—■—); DHA/EPA (2:1) group, n 34 (---▲---).

experiments used in the present study were in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) regarding mammalian research.

Results

DHA/EPA (2:1) improve the survival rate of mice infected with *Pseudomonas aeruginosa*

In the control mice, *P. aeruginosa* infection induced 68% mortality within 6 d and most of these mice (51%) died within 48 h after the onset of *P. aeruginosa* lung infection (Fig. 1(a)). The survival rate of mice fed the alkylglycerol diet was similar to that of the control mice (Fig. 1(a)). Interestingly, the DHA/EPA (2:1)-enriched diet significantly increased the resistance to *P. aeruginosa* infection starting at day 2 after the instillation of the bacteria ($P < 0.05$ *v.* control diet; log-rank test; Fig. 1(a)).

The alkylglycerol- and DHA/EPA (2:1)-enriched diets did not affect body mass before or after the onset of *P. aeruginosa* lung infection. A significant body mass loss was measured

2 and 3 d after the instillation of *P. aeruginosa* infection in each group. However, the loss did not exceed 15% of the initial body mass (Fig. 1(b)). Of those mice that survived the infection, body mass started to increase at day 4, leading to the full recovery of the initial body mass 7 d after infection in the alkylglycerol and DHA/EPA (2:1) groups and 9 d after infection in the control group (Fig. 1(b)).

DHA/EPA (2:1) accelerate bacterial clearance in the lungs

None of the diets affected the bacterial load in the lungs during the first 8 h of infection ($10^{6.73}$ (SEM $10^{0.14}$) *v.* $10^{6.02}$ (SEM $10^{0.37}$) and $10^{6.94}$ (SEM $10^{0.16}$) bacteria/lung in the control, alkylglycerol and DHA/EPA (2:1) groups, respectively; Fig. 2). Mice fed with the control and alkylglycerol-enriched diets exhibited a similar bacterial load at all time points of the experiment ($10^{6.73}$ (SEM $10^{0.14}$), $10^{6.24}$ (SEM $10^{0.67}$) and $10^{5.81}$ (SEM $10^{0.55}$) bacteria/lung in the control group; $10^{6.02}$ (SEM $10^{0.37}$), $10^{4.91}$ (SEM $10^{0.62}$) and $10^{6.23}$ (SEM $10^{0.33}$) bacteria/lung in the alkylglycerol group at 8, 24 and 36 h after infection, respectively; Fig. 2). Interestingly, mice fed with the DHA/EPA (2:1)-enriched diet exhibited accelerated bacterial clearance compared with the control mice. At 24 h after infection, the lung concentration of *P. aeruginosa* was significantly lower when compared with the control mice ($10^{4.52}$ (SEM $10^{0.63}$) *v.* $10^{6.24}$ (SEM $10^{0.67}$) bacteria/lung in the DHA/EPA (2:1) and control groups, respectively; $P < 0.05$; two-way ANOVA; Fig. 2).




Fig. 2. Impact of diets enriched in DHA/EPA (2:1) and alkylglycerols on bacterial clearance following the onset of *Pseudomonas aeruginosa* pulmonary infection. Data represent the ratio between the number of bacteria collected and the weight of the lungs from each mouse. Briefly, the lungs excised from mice in each group at 8, 24 and 36 h after the onset of the infection were homogenised in 0.9% sterile saline solution. Serial dilutions of the homogenates were inoculated on bromocresol agar plates for 24 h at 37°C in order to determine the number of *P. aeruginosa* colony-forming units. Values are means (n 7–14 mice per group), with standard errors represented by vertical bars. *Mean value was significantly lower 24 h after *P. aeruginosa* infection in the lungs of mice fed with DHA/EPA (2:1) compared with the control mice at the same time of infection ($P < 0.05$; two-way ANOVA). ††Mean value was significantly different from that at 8 h in the DHA/EPA (2:1) group ($P < 0.01$; two-way ANOVA). The numbers on top of the bars are the number of mice per group. □, Control; ▨, alkylglycerol; ▤, DHA/EPA (2:1).




Fig. 3. Impact of diets enriched in DHA/EPA (2:1) and alkylglycerols on the recruitment of immune cells following the onset of *Pseudomonas aeruginosa* pulmonary infection. Data represent the number of neutrophils (a) and macrophages (b) in the bronchoalveolar lavage fluid (BALF) collected at 8, 16 and 36 h after the onset of the infection from mice in each group. Briefly, bronchoalveolar lavages were performed with a blunt 20 G needle by injecting/reaspirating 0.5 ml followed by 1 ml of 0.9% sterile saline solution in the trachea of mice from each group at 8, 16 and 36 h after the onset of the infection. The cells collected were organised in monolayers with a cytocentrifuge and stained with Wright–Giemsa solutions in order to determine and count the morphotypes. Values are means, with standard errors represented by vertical bars. Mean value was significantly lower 36 h after *P. aeruginosa* infection compared with the control mice: * $P < 0.05$, ** $P < 0.01$ (two-way ANOVA). Mean value was significantly lower than that at 36 h after *P. aeruginosa* infection in the same group: † $P < 0.05$, †† $P < 0.01$, ††† $P < 0.001$ (two-way ANOVA). The numbers on top of the bars are the number of mice per group. □, Control; ▨, alkylglycerols; ▩, DHA/EPA (2:1).

Fish oils attenuate the influx of neutrophils towards the lungs

The neutrophil granulocyte is a major participant in the early phases of acute inflammatory response in tissues⁽¹⁷⁾. Accordingly, neutrophils were the predominant cell population observed in the BALF collected from mice in each group at all time points of infection. *P. aeruginosa* induced a continuous and significant influx of neutrophils in the BALF of mice fed the control and alkylglycerol-enriched diets during the course of infection (3.5×10^5 (SEM 4.6×10^4) and 1.5×10^6 (SEM 2.2×10^5) cells/ml; 2.4×10^5 (SEM 4.5×10^4) and 1.2×10^6 (SEM 2.4×10^5) cells/ml in the control and alkylglycerol groups at 8 and 36 h, respectively; $P < 0.001$ in the control group and

$P < 0.01$ in the alkylglycerol group; two-way ANOVA; Fig. 3(a)). Interestingly, despite a similar pattern of recruitment between these two groups, mice fed the alkylglycerol-enriched diet exhibited attenuated infiltration of the lungs by neutrophils at 36 h after the onset of the infection when compared with the control mice (1.2×10^6 (SEM 2.4×10^5) v. 1.9×10^6 (SEM 4.2×10^5) cells/ml in the alkylglycerol and control groups, respectively; $P < 0.05$; two-way ANOVA; Fig. 3(a)). Similarly, the DHA/EPA-enriched diet was associated with a significant decrease in neutrophils detected in the lungs at 36 h after the onset of the infection (1.1×10^6 (SEM 1.9×10^5) cells/ml in the DHA/EPA (2:1) group v. 1.9×10^6 (SEM 4.2×10^5) cells/ml in the control group; $P < 0.01$; two-way ANOVA; Fig. 3(a)). As a result, only a modest non-significant increase in neutrophils was observed in the infected lungs of these mice during the course of infection (Fig. 3(a)).

Alkylglycerols decrease macrophage colonisation in the lungs

Alveolar macrophages play an important role in resolving inflammation⁽¹⁸⁾. *P. aeruginosa* infection induced a continuous recruitment of macrophages in the BALF of the control and DHA/EPA (2:1) groups during the course of infection (Fig. 3(b)). Moreover, according to their role, pulmonary colonisation reached a maximum 36 h after the onset of the infection in these two groups (1.03×10^5 (SEM 2.3×10^4) v. 3.11×10^4 (SEM 5.7×10^3) cells/ml and 9.30×10^4 (SEM 2.9×10^4) v. 2.19×10^5 (SEM 4.0×10^3) cells/ml in the control and DHA/EPA (2:1) groups at 36 v. 8 h, respectively; $P < 0.01$ in the control and DHA/EPA (2:1) groups; two-way ANOVA; Fig. 3(b)). Interestingly, the number of macrophages in the BALF of the alkylglycerol group remained comparable at all time points of infection (1.60×10^4 (SEM 3.12×10^3), 4.18×10^4 (SEM 8.13×10^3) and 4.88×10^4 (SEM 7.70×10^3) cells/ml in the alkylglycerol group at 8, 16 and 36 h, respectively; Fig. 3(b)). This pattern of colonisation led to a significant decrease in macrophage infiltration in the lungs of the alkylglycerol group when compared with the control group at a later stage of infection (4.88×10^4 (SEM 7.70×10^3) and 1.03×10^5 (SEM 2.30×10^4) cells/ml in the control and alkylglycerol groups, respectively, at 36 h; $P < 0.05$; two-way ANOVA; Fig. 3(b)).

DHA/EPA (2:1) increase TNF- α secretion in the lungs

In the control and alkylglycerol groups, *P. aeruginosa* infection was associated with the similar levels of TNF- α at 8 and 16 h after the onset of the infection (1516 (SEM 256) and 2516 (SEM 516) pg/ml; 2145 (SEM 241) and 2030 (SEM 488) pg/ml in the control and alkylglycerol groups at 8 and 16 h, respectively; Fig. 4(a)). Then, TNF- α secretion decreased in both groups but without reaching significance in the alkylglycerol group (866 (SEM 81) v. 2030 (SEM 488) and 522 (SEM 144) v. 2516 (SEM 516) pg/ml at 36 and 16 h in the alkylglycerol and control groups, respectively; $P < 0.01$ in the control group; Fig. 4(a)). Interestingly, *P. aeruginosa* infection triggered a peak secretion of TNF- α at 16 h after the onset of the infection in the DHA/EPA (2:1) group (3951 (SEM 671) v. 1791 (SEM 283)




Fig. 4. Inflammatory status after the onset of *Pseudomonas aeruginosa* infection in mice fed the control (□), alkylglycerol- (▤) or DHA/EPA (2:1)-enriched (▨) diets. Cytokines were evaluated in the bronchoalveolar lavage fluid (BALF) for TNF- α and in lung homogenates for IL-10 using ELISA kits. (a) Data represent the concentration of TNF- α in the BALF collected from mice in each group. Values are means (n 7–17 mice per group), with standard errors represented by vertical bars. *Mean value was significantly higher 16 h after *P. aeruginosa* infection compared with the control mice (P < 0.05; two-way ANOVA). Mean value was significantly lower than that at 16 h after *P. aeruginosa* infection in the same group: †† P < 0.01, ††† P < 0.001 (two-way ANOVA). (b) Data represent the concentration of IL-10 extracted from the lungs of mice in each group. Values are means (n 7–17 mice per group), with standard errors represented by vertical bars. ***Mean value was significantly higher 24 h after *P. aeruginosa* infection compared with the control mice (P < 0.0001; two-way ANOVA). Mean value was significantly lower than that at 24 h after *P. aeruginosa* infection in the same group: † P < 0.05, ††† P < 0.0001 (two-way ANOVA). The numbers on top of the bars are the number of mice per group.

and 1162 (SEM 123) pg/ml at 16, 8 and 36 h, respectively; P < 0.001; two-way ANOVA; Fig. 4(a)). Moreover, at this time point, the TNF- α level was significantly higher than that of the control group (3951 (SEM 671) *v.* 2515 (SEM 516) pg/ml at 16 h in the DHA/EPA (2:1) and control groups, respectively; P < 0.05; two-way ANOVA; Fig. 4(a)).

DHA/EPA (2:1) increase IL-10 secretion in the lungs

The anti-inflammatory cytokine IL-10 plays an important role in the resolution of inflammation promoted by *P. aeruginosa* infection^(19,20). None of the diets affected IL-10 secretion in

the lungs of mice in each group 8 h after the onset of the infection. The control, alkylglycerol and DHA/EPA (2:1) groups exhibited a significant increase in IL-10 secretion in the lungs 24 h after the onset of *P. aeruginosa* infection (11.3 (SEM 1.2) *v.* 5.0 (SEM 0.7) ng/g of lungs; 15.6 (SEM 2.6) *v.* 4.9 (SEM 1.1) ng/g of lungs and 20.8 (SEM 2.5) *v.* 5.7 (SEM 0.4) ng/g of lungs in the control, alkylglycerol and DHA/EPA (2:1) groups at 24 and 8 h, respectively; P < 0.05 in the control group and P < 0.001 in the alkylglycerol and DHA/EPA (2:1) groups; two-way ANOVA; Fig. 4(b)). Interestingly, the peak observed in mice fed with the DHA/EPA (2:1)-enriched diet was significantly higher than that observed in the control group (20.8 (SEM 2.5) *v.* 11.3 (SEM 1.2) ng/g of lungs; P < 0.001; two-way ANOVA; Fig. 4(b)). At 36 h after the onset of *P. aeruginosa* infection, alkylglycerol- and DHA/EPA (2:1)-fed mice exhibited a significant decrease in IL-10 secretion, leading to values comparable to those measured at 8 h after the onset of the infection (5.97 (SEM 0.66) *v.* 4.90 (SEM 1.14) ng/g of lungs and 5.92 (SEM 1.4) *v.* 5.67 (SEM 0.41) ng/g of lungs in the alkylglycerol and DHA/EPA (2:1) groups at 36 and 8 h, respectively; P < 0.001; two-way ANOVA; Fig. 4(b)).

Fish oils do not affect lung permeability

Alveolar–capillary barrier permeability was used as a marker of pulmonary injuries in mice infected with *P. aeruginosa*. The diets did not affect alveolar–capillary barrier permeability in the lungs during the first 8 h of infection (3.5 (SEM 0.3), 3.3 (SEM 0.5) and 4.5 (SEM 0.4) % in the control, alkylglycerol and DHA/EPA (2:1) groups, respectively; Fig. 5). A significant decrease in alveolar–capillary barrier permeability was observed at 16 h after the onset of the infection in the DHA/EPA (2:1) group, but without reaching significance when compared with the control group (2.5 (SEM 0.5) *v.* 4.5 (SEM 0.4) % in the DHA/EPA (2:1) group at 16 and 8 h, respectively; P < 0.05; two-way ANOVA; 2.5 (SEM 0.5) *v.* 3.5 (SEM 0.4) % in the DHA/EPA (2:1) and control groups at 16 h after the onset of the infection, respectively; Fig. 5).

Discussion

The present study showed that DHA/EPA supplementation in a 2:1 ratio improved the outcomes of *P. aeruginosa* infection in a more efficient manner than supplementation with alkylglycerols. Thus, supplementation of the DHA/EPA (2:1)-enriched diet for 5 weeks improves the survival rate in our mouse model of acute *P. aeruginosa* pulmonary infection via a specific pattern of cytokine secretion and neutrophil influx. Indeed, DHA/EPA (2:1) supplementation induces a high level of the pro-inflammatory cytokine TNF- α and a high secretion of the anti-inflammatory cytokine IL-10. In addition, supplementation with DHA/EPA (2:1) limits the influx of neutrophils in the lungs in response to *P. aeruginosa* infection. Together, these events are associated with significant bacterial clearance, leading to an improvement of survival.

We previously demonstrated in wild-type and *cflr*^{-/-} mice that 5 weeks of supplementation with the same quantity of




Fig. 5. Impact of diets enriched in DHA/EPA (2:1) and alkylglycerols on pulmonary injuries following the onset of *Pseudomonas aeruginosa* infection. Data represent the proportion of fluorescence detected in the bronchoalveolar lavage fluid v. serum collected by cardiac puncture 2 h after intraperitoneal injection of albumin-fluorescein isothiocyanate (FITC) (0.2 mg/mouse) in mice from each group. Values are means (n 8–14 mice per group), with their standard errors represented by vertical bars. *Mean value was significantly lower 16 h after *P. aeruginosa* infection in mice fed with the DHA/EPA (2:1)-enriched diet compared with 8 h in the same group ($P < 0.05$; two-way ANOVA). The numbers on top of the bars are the number of mice per group. □, Control; ▨, alkylglycerols; ▩, DHA/EPA (2:1).

DHA/EPA but with an inverted 1:2 ratio is enough to modulate fatty acid incorporation in phospholipid membranes and to improve the outcomes of acute and chronic lung infection with *P. aeruginosa*^(7,21). A growing number of studies have suggested that DHA demonstrates immunomodulatory and anti-inflammatory functions in a wide variety of inflammatory diseases^(22–25), besides its well-documented action in the maturation of the nervous system (for a review, see Miles & Calder⁽⁶⁾ and Larque *et al.*⁽²⁶⁾). However, divergences in the anti-infectious actions of these compounds in the outcomes of infections by influenza virus or *Citrobacter rodentium* raised the question of the extraction/purification of the lipids, as well as the doses and optimal ratio of EPA and DHA needed in a mixture of fatty acids to reach a significant anti-infectious effect^(27–29). These aspects of the impact of EPA and DHA on the immune system mainly remain unclear because of the lack of dose–response studies (for a review, see Calder⁽³⁰⁾). One other important finding in the present study is that the fatty acid mixture naturally extracted from rays and enriched in DHA/EPA (2:1) demonstrates strong anti-infectious properties associated with a global anti-inflammatory effect, opening the field for a future human clinical trial.

Indeed, we showed that a DHA/EPA (2:1)-enriched diet tends to increase the influx of neutrophils in the lungs at the early stage of infection, although this influx was significantly reduced during the later stage of infection. These cells represent the first line of defence against bacterial infections by orchestrating activities leading to the destruction of pathogens⁽³¹⁾. The prominence of *P. aeruginosa* sepsis in neutropenic patients highlights the critical role of neutrophils in defence against this pathogen⁽³²⁾. In contrast, it is also well known that patients with cystic fibrosis suffer from chronic inflammation because of persistent pulmonary colonisation

by neutrophils^(33,34). In this way, Freedman *et al.*⁽³⁵⁾ showed that restoration of the DHA level in the cell membranes of *cfr*^{−/−} mice by oral supplementation of DHA leads to the normalisation of neutrophil influx in the lungs after the onset of *P. aeruginosa* infection. This effect was not observed in wild-type mice, leading the authors to conclude that DHA could not directly act on the mediators of inflammation. Here, we show that even in the context of a balanced level of DHA in cell membranes, a DHA/EPA (2:1)-enriched diet could play a major role in preventing chronic inflammation by improving the influx of neutrophils towards the site of infection. The duration of the diet and/or the association with EPA, also known to improve the outcomes of *P. aeruginosa* infection^(7,8), could explain the differences observed. However, to provide isolipidic–isoenergetic diets to our three groups of mice, the SFA content was decreased in the DHA/EPA (2:1) diet compared with the control and alkylglycerol diets. Also, SFA are well known to promote inflammation (for a review, see Calder⁽³⁰⁾). So, we cannot rule out the impact of the decreased level of SFA in our DHA/EPA (2:1) diet. However, Freedman *et al.*⁽³⁵⁾ showed a significant and beneficial impact of DHA alone without modifications of SFA, suggesting that the limitation of neutrophil influx observed here results at least from the combination of DHA/EPA (2:1) and the decreased level of SFA, if not DHA/EPA (2:1) alone.

The DHA/EPA (2:1)-enriched diet is associated with a concomitant increase in IL-10 and TNF- α secretion during the infection. IL-10 decreases lung inflammation by limiting neutrophil influx and promoting their apoptosis^(19,20,36–38). Accordingly, in our model, DHA/EPA (2:1) enhance the peak secretion of IL-10 at 24 h after the onset of the infection followed by attenuation of neutrophil influx in the lungs at 36 h after the onset of *P. aeruginosa* infection. Concomitantly, we measured a high level of TNF- α secretion in DHA/EPA (2:1)-fed mice. We previously observed a concomitant and equivalent rise of TNF- α and IL-10 secretion in mice fed with DHA/EPA with an inverted 1:2 ratio and subjected to acute *P. aeruginosa* infection⁽⁸⁾. In the same way, the increased level of TNF- α was not associated with increased bacterial load or neutrophil influx in our protocol. In that study⁽⁸⁾, despite notable changes in the inflammatory and immune responses of mice fed with the DHA/EPA (1:2)-enriched diet, no significant improvement of survival was observed. However, the pattern of cell recruitment was not improved with the DHA/EPA (1:2) diet as it is with our DHA/EPA (2:1) diet. These results suggest that DHA exhibits more potent anti-infectious actions than EPA, partly by optimising a coordinated cell immunity response at the site of infection. TNF- α has been shown to play a significant role in priming and activating neutrophils in patients with cystic fibrosis, enhancing lung injuries and leading to chronic inflammation⁽³⁹⁾. However, inflammation is needed to eradicate the invading pathogens^(27,40), so the anti-inflammatory effect of *n*-3 LC-PUFA could be deleterious. Here we show that besides its anti-inflammatory role, the DHA/EPA (2:1) diet triggers a high level of the pro-inflammatory cytokine TNF- α during *P. aeruginosa* infection, and this may participate in the beneficial effect of the diet on the outcomes of the infection.

Indeed, Murray *et al.*⁽⁴¹⁾ showed that TNF- α is an important factor implicated in neutrophil apoptosis by binding to TNF- α receptors 55 and 75. In our model, we observed a decreased influx of neutrophils towards the end of the infection, following the significant increase in TNF- α secretion and concomitantly with an increase in macrophage influx towards the lungs. So, one could speculate that the high level of TNF- α combined with macrophage influx observed in DHA/EPA (2:1)-fed mice leads to neutrophil apoptosis and removal from the lungs. Ultimately, the high secretion of TNF- α promoted by the DHA/EPA (2:1) diet in our model compensates the anti-inflammatory impact of the diet, and leads to a decrease of the pathogen in the lungs and an increase in the survival rate.

We did not observe an improvement in resistance to acute *P. aeruginosa* pulmonary infection in mice fed the alkylglycerol-enriched diet. More importantly, our model did not confirm the anti-bacterial effect of alkylglycerols that was previously observed *in vitro*^(14,15). However, previous studies emphasised high variability in the anti-bacterial effect of these compounds depending on the type of fatty acids linked to glycerol, the dose of alkylglycerols and the species of bacteria. In our protocol, the mix of alkylglycerols used to feed the mice was particularly enriched in long-chain fatty acids such as C18 (data not shown), which could explain the absence of the anti-bacterial effect observed in our model. In addition, although our laboratory previously demonstrated that dietary supplementation for 5 weeks is sufficient to increase the incorporation of *n*-3 PUFA in the plasma membrane^(7,8), the duration of the diet and the concentration of alkylglycerols needed to reach a significant incorporation of alkylglycerols in tissues have been poorly documented. Previously, similar doses of alkylglycerols (10 g/kg diet) have been shown to be highly incorporated in various tissues of mice, including lungs, after 4 weeks of diet⁽⁴²⁾. Interestingly, we observed that the diet and the protocol used in the present study tended to modulate the immune system of mice subjected to acute *P. aeruginosa* infection, such as macrophage and neutrophil influx and TNF- α secretion, suggesting that higher doses and/or longer duration of the diet may modulate the outcomes of acute *P. aeruginosa* pulmonary infection in mice.

Conclusion

We demonstrate that DHA/EPA in a 2:1 ratio increase the survival rate in our mouse model of acute *P. aeruginosa* pulmonary infection. The DHA/EPA (2:1) diet triggers high levels of IL-10 and TNF- α secretion, preventing the persistent influx of neutrophils towards the site of infection. Altogether, these events lead to a significant decrease in bacterial load, increasing survival to the infection. Overall, we showed that the DHA/EPA (2:1)-enriched diet improves coordinated responses of the immune system to bacterial infection. In contrast, alkylglycerols did not significantly improve survival to *P. aeruginosa* infection at the dose and duration of the diet used. However, significant changes in macrophage and neutrophil influx as well as slight variations in TNF- α secretion were observed, suggesting that a higher dose and/or longer duration of the diet might have a significant

impact on immune functions. Finally, DHA/EPA (2:1) and alkylglycerols do not seem to activate the same pathways, suggesting that a combination of both lipids warrants further research in the prevention of *P. aeruginosa* infection.

Acknowledgements

The present study was funded by a 'seaminoil' grant – a project supported by FUI (Fonds Unique Interministériel) aiming at adding value to unused fish by-products – and financially supported by Nutricia Research.

The authors' contributions are as follows: E. C., M.-O. H. and F. G. conceived and designed the experiments; L. S. and N. B. contributed unpublished reagents/analytic tools; E. C. performed the experiments; E. C., J.-L. D., M.-O. H., A. D. and F. G. analysed the data; E. C. and F. G. wrote the paper. All authors read and approved the final manuscript.

The authors have no conflict of interest to declare.

References

1. Oliver A, Canton R, Campo P, *et al.* (2000) High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* **288**, 1251–1254.
2. Davies JC (2002) *Pseudomonas aeruginosa* in cystic fibrosis: pathogenesis and persistence. *Paediatr Respir Rev* **3**, 128–134.
3. Cantin A (1995) Cystic fibrosis lung inflammation: early, sustained, and severe. *Am J Respir Crit Care Med* **151**, 939–941.
4. Lyczak JB, Cannon CL & Pier GB (2002) Lung infections associated with cystic fibrosis. *Clin Microbiol Rev* **15**, 194–222.
5. Davis PB, Drumm M & Konstan MW (1996) Cystic fibrosis. *Am J Respir Crit Care Med* **154**, 1229–1256.
6. Miles EA & Calder PC (2012) Influence of marine *n*-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *Br J Nutr* **107**, Suppl. 2, S171–S184.
7. Pierre M, Husson MO, Le Berre R, *et al.* (2007) Omega-3 polyunsaturated fatty acids improve host response in chronic *Pseudomonas aeruginosa* lung infection in mice. *Am J Physiol Lung Cell Mol Physiol* **292**, L1422–L1431.
8. Tieset H, Pierre M, Desseyn JL, *et al.* (2009) Dietary (*n*-3) polyunsaturated fatty acids affect the kinetics of pro- and antiinflammatory responses in mice with *Pseudomonas aeruginosa* lung infection. *J Nutr* **139**, 82–89.
9. Anderson BM & Ma DW (2009) Are all *n*-3 polyunsaturated fatty acids created equal? *Lipids Health Dis* **8**, 33.
10. Yamamoto N, St Claire DA Jr, Homma S, *et al.* (1988) Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. *Cancer Res* **48**, 6044–6049.
11. Homma S, Millman I & Yamamoto N (1990) A serum factor for macrophage activation after *in vitro* dodecylglycerol treatment of mouse lymphocytes. *Immunol Cell Biol* **68**, 137–142.
12. Ngwenya BZ, Fiavey NP & Mogashoa MM (1991) Activation of peritoneal macrophages by orally administered ether analogues of lysophospholipids. *Proc Soc Exp Biol Med* **197**, 91–97.
13. Mitre R, Etienne M, Martinais S, *et al.* (2005) Humoral defence improvement and haematopoiesis stimulation in sows and offspring by oral supply of shark-liver oil to

- mothers during gestation and lactation. *Br J Nutr* **94**, 753–762.
14. Ved HS, Gustow E, Mahadevan V, *et al.* (1984) Dodecylglycerol. A new type of antibacterial agent which stimulates autolysin activity in *Streptococcus faecium* ATCC 9790. *J Biol Chem* **259**, 8115–8121.
15. Brissette JL, Cabacungan EA & Pieringer RA (1986) Studies on the antibacterial activity of dodecylglycerol. Its limited metabolism and inhibition of glycerolipid and lipoteichoic acid biosynthesis in *Streptococcus mutans* BHT. *J Biol Chem* **261**, 6338–6345.
16. Reeves PG, Rossow KL & Lindlauf J (1993) Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. *J Nutr* **123**, 1923–1931.
17. Phillipson M & Kubes P (2011) The neutrophil in vascular inflammation. *Nat Med* **17**, 1381–1390.
18. Krysko O, Vandenabeele P, Krysko DV, *et al.* (2010) Impairment of phagocytosis of apoptotic cells and its role in chronic airway diseases. *Apoptosis* **15**, 1137–1146.
19. Armstrong L, Jordan N & Millar A (1996) Interleukin 10 (IL-10) regulation of tumour necrosis factor α (TNF- α) from human alveolar macrophages and peripheral blood monocytes. *Thorax* **51**, 143–149.
20. Cox G (1996) IL-10 enhances resolution of pulmonary inflammation *in vivo* by promoting apoptosis of neutrophils. *Am J Physiol* **271**, L566–L571.
21. Tieset H, Bernard H, Bartke N, *et al.* (2011) (n-3) Long-chain PUFA differentially affect resistance to *Pseudomonas aeruginosa* infection of male and female *cfr*^{-/-} mice. *J Nutr* **141**, 1101–1107.
22. Lee SE, Lim JW, Kim JM, *et al.* (2014) Anti-inflammatory mechanism of polyunsaturated fatty acids in *Helicobacter pylori*-infected gastric epithelial cells. *Mediators Inflamm* **2014**, 128919.
23. Naqvi AZ, Hasturk H, Mu L, *et al.* (2014) Docosahexaenoic acid and periodontitis in adults: a randomized controlled trial. *J Dent Res* **93**, 767–773.
24. Oh DY, Walenta E, Akiyama TE, *et al.* (2014) A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. *Nat Med* **20**, 942–947.
25. Cleland LG, Caughey GE, James MJ, *et al.* (2006) Reduction of cardiovascular risk factors with long-term fish oil treatment in early rheumatoid arthritis. *J Rheumatol* **33**, 1973–1979.
26. Larque E, Gil-Sanchez A, Prieto-Sanchez MT, *et al.* (2012) Omega 3 fatty acids, gestation and pregnancy outcomes. *Br J Nutr* **107**, Suppl. 2, S77–S84.
27. Schwerbrock NM, Karlsson EA, Shi Q, *et al.* (2009) Fish oil-fed mice have impaired resistance to influenza infection. *J Nutr* **139**, 1588–1594.
28. Morita M, Kuba K, Ichikawa A, *et al.* (2013) The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. *Cell* **153**, 112–125.
29. Hekmatdoost A, Wu X, Morampudi V, *et al.* (2013) Dietary oils modify the host immune response and colonic tissue damage following *Citrobacter rodentium* infection in mice. *Am J Physiol Gastrointest Liver Physiol* **304**, G917–G928.
30. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Br J Clin Pharmacol* **75**, 645–662.
31. Lotz S, Aga E, Wilde I, *et al.* (2004) Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. *J Leukoc Biol* **75**, 467–477.
32. Maschmeyer G & Braveny I (2000) Review of the incidence and prognosis of *Pseudomonas aeruginosa* infections in cancer patients in the 1990s. *Eur J Clin Microbiol Infect Dis* **19**, 915–925.
33. Bonfield TL, Konstan MW & Berger M (1999) Altered respiratory epithelial cell cytokine production in cystic fibrosis. *J Allergy Clin Immunol* **104**, 72–78.
34. Chmiel JF & Davis PB (2003) State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? *Respir Res* **4**, 8.
35. Freedman SD, Katz MH, Parker EM, *et al.* (1999) A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in *cfr*^{-/-} mice. *Proc Natl Acad Sci U S A* **96**, 13995–14000.
36. Dang PM, Elbim C, Marie JC, *et al.* (2006) Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity. *FASEB J* **20**, 1504–1506.
37. Cassatella MA, Meda L, Bonora S, *et al.* (1993) Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. *J Exp Med* **178**, 2207–2211.
38. Chmiel JF, Konstan MW, Saadane A, *et al.* (2002) Prolonged inflammatory response to acute *Pseudomonas* challenge in interleukin-10 knockout mice. *Am J Respir Crit Care Med* **165**, 1176–1181.
39. Taggart C, Coakley RJ, Grealley P, *et al.* (2000) Increased elastase release by CF neutrophils is mediated by tumor necrosis factor- α and interleukin-8. *Am J Physiol Lung Cell Mol Physiol* **278**, L33–L41.
40. Ghosh S, DeCoffe D, Brown K, *et al.* (2013) Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. *PLOS ONE* **8**, e55468.
41. Murray J, Barbara JA, Dunkley SA, *et al.* (1997) Regulation of neutrophil apoptosis by tumor necrosis factor- α : requirement for TNFR55 and TNFR75 for induction of apoptosis *in vitro*. *Blood* **90**, 2772–2783.
42. Weber N (1985) Metabolism of orally administered *rac*-1-O-[1'-¹⁴C]dodecylglycerol and nutritional effects of dietary *rac*-1-O-dodecylglycerol in mice. *J Lipid Res* **26**, 1412–1420.